Notably, it has been proven that the survival advantage conferred by BCL-xL expression is pivotal to sustaining Cisplatin resistance in ovarian, lung, and oral cancer cells while downregulating BCL-xL sensitizes these cells effectively to the toxic effects of Cisplatin [52,53,54]. Here, BCL2L1 is linked to lip and oral cavity carcinoma.